Thoracic cancer · 2026
Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ariyasu Ryo, Nemoto Teruhisa, Iso Hirokazu, Ito Masahiro, Nibuya Kyujiro, Fujishima Syunsuke, Sugai Mayu, Tsugitomi Ryosuke, Amino Yoshiaki, Uchibori Ken, Yanagitani Noriko, Nishio Makoto
Аннотация
INTRODUCTION: Therapeutic progress for extensive-stage small-cell lung cancer (ES-SCLC) has been limited. Although immune checkpoint inhibitors (ICIs) have been introduced, their real-world impact on survival remains uncertain. We evaluated 25-year survival trends and the association between ICI exposure and overall survival (OS).
METHODS: Consecutive ES-SCLC patients treated at a Japanese cancer center between April 1999 and March 2023 were retrospectively reviewed and grouped by diagnosis period: A (1999-2003), B (2004-2008), C (2009-2013), D (2014-2018), and E (2019-2023). OS from diagnosis to death was measured. Kaplan-Meier/log-rank tests and multivariable Cox models were used. Subgroup analyses included patients aged ≥ 75 years, with PS ≥ 2, and with brain metastases.
RESULTS: A total of 452 patients were included. Median OS in period A was 9.8 months and in periods B-E, it was 12.5, 13.4, 11.8, and 13.6 months; 2-year OS rates were 6.2%, 18.2%, 18.6%, 17.3%, and 28.9%, respectively. In multivariable analysis, PS ≥ 2 (HR 1.51), receipt of first-line therapy (HR 0.09), and ICI exposure (HR 0.73; p = 0.013) were independently associated with OS. ICI exposure was associated with longer OS (15.2 vs. 12.3 months; 2-year OS 32.1% vs. 15.9%; p < 0.005) among systemically treated patients. In subgroup analyses, ICI-associated HRs were 0.67 in patients aged ≥ 75 years, 0.69 in PS ≥ 2, and 0.63 in brain metastases.
CONCLUSIONS: Real-world survival in ES-SCLC improved over 25 years. ICI exposure was independently associated with improved OS, as well as in clinically high-risk subgroups.
METHODS: Consecutive ES-SCLC patients treated at a Japanese cancer center between April 1999 and March 2023 were retrospectively reviewed and grouped by diagnosis period: A (1999-2003), B (2004-2008), C (2009-2013), D (2014-2018), and E (2019-2023). OS from diagnosis to death was measured. Kaplan-Meier/log-rank tests and multivariable Cox models were used. Subgroup analyses included patients aged ≥ 75 years, with PS ≥ 2, and with brain metastases.
RESULTS: A total of 452 patients were included. Median OS in period A was 9.8 months and in periods B-E, it was 12.5, 13.4, 11.8, and 13.6 months; 2-year OS rates were 6.2%, 18.2%, 18.6%, 17.3%, and 28.9%, respectively. In multivariable analysis, PS ≥ 2 (HR 1.51), receipt of first-line therapy (HR 0.09), and ICI exposure (HR 0.73; p = 0.013) were independently associated with OS. ICI exposure was associated with longer OS (15.2 vs. 12.3 months; 2-year OS 32.1% vs. 15.9%; p < 0.005) among systemically treated patients. In subgroup analyses, ICI-associated HRs were 0.67 in patients aged ≥ 75 years, 0.69 in PS ≥ 2, and 0.63 in brain metastases.
CONCLUSIONS: Real-world survival in ES-SCLC improved over 25 years. ICI exposure was independently associated with improved OS, as well as in clinically high-risk subgroups.